跳至主要内容
临床试验/CTRI/2023/07/055558
CTRI/2023/07/055558招募中Unknown

An Observational Real World Data Collection to Assess Effectiveness & Safety of Nimotuzumab in Cisplatin ineligible Locally Advanced Head and Neck Cancer

Biocon Biologics Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Histologically and cytologically confirmed diagnosis of locally advanced head and neck squamous cell carcinoma (LAHNSCC)
  • Adults of either sex, between 18 years or above who have been prescribed Nimotuzumab in routine clinical practice
  • Patients with Renal dysfunction, Hearing impairment, Neuropathy, or patients unfit for cisplatin therapy as per physician’s discretion
  • Patients with Marrow, Respiratory, Cardiovascular, and Hepatic dysfunctions

排除标准

  • Patients will not be eligible if known or suspected hypersensitivity to compounds with similarity to Nimotuzumab or Pregnant or lactating women or Patients who decline consent

研究者

相似试验